Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Alphamab Oncology's Enterprise Value is HK$6,451.9 Mil.
Alphamab Oncology's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-117.9 Mil. Therefore, Alphamab Oncology's EV-to-EBIT ratio for today is -54.70.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Alphamab Oncology's Enterprise Value is HK$6,451.9 Mil.
Alphamab Oncology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-46.9 Mil. Therefore, Alphamab Oncology's EV-to-EBITDA ratio for today is -137.71.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Alphamab Oncology's Enterprise Value is HK$6,451.9 Mil.
Alphamab Oncology's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was HK$621.8 Mil. Therefore, Alphamab Oncology's EV-to-Revenue ratio for today is 10.38.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Alphamab Oncology's Enterprise Value is HK$6,451.9 Mil.
Alphamab Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-169.3 Mil. Therefore, Alphamab Oncology's EV-to-FCF ratio for today is -38.11.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Alphamab Oncology (HKSE:09966) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Alphamab Oncology's current Enterprise Value is HK$6,451.9 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Alphamab Oncology's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-117.9 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Alphamab Oncology's current Enterprise Value is HK$6,451.9 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Alphamab Oncology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-46.9 Mil.
Alphamab Oncology's current Enterprise Value is HK$6,451.9 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Alphamab Oncology's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was HK$621.8 Mil.
Alphamab Oncology's current Enterprise Value is HK$6,451.9 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Alphamab Oncology's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-134.6 Mil.
Alphamab Oncology's current Enterprise Value is HK$6,451.9 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Alphamab Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-169.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alphamab Oncology Enterprise Value Related Terms
Alphamab Oncology Enterprise Value Historical Data
* Premium members only.
The historical data trend for Alphamab Oncology's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:09966 vs VRTX, REGN, RVMD: Enterprise Value Comparison
For the Biotechnology subindustry, Alphamab Oncology's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alphamab Oncology Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alphamab Oncology's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Alphamab Oncology's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Alphamab Oncology's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of HK$6,451.9 Mil mean?
Alphamab Oncology (HKSE:09966) has a Enterprise Value of HK$6,451.9 Mil as of Aug. 20, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Alphamab Oncology and its competitors.
Is Alphamab Oncology's Enterprise Value too high?
Alphamab Oncology's current Enterprise Value is HK$6,451.9 Mil. Overall, Alphamab Oncology has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Alphamab Oncology's Enterprise Value compare to VRTX and REGN?
Alphamab Oncology's Enterprise Value of HK$6,451.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Alphamab Oncology and its competitors. Alphamab Oncology's current Enterprise Value is HK$6,451.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alphamab Oncology stock overvalued right now?
Based on GuruFocus' analysis, Alphamab Oncology (HKSE:09966) is currently considered Fairly Valued. The stock's GF Value™ is HK$7.81, compared to a current price of HK$8.35 — trading 6.9% above its estimated fair value. The current Enterprise Value is HK$6,451.9 Mil. Alphamab Oncology's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Alphamab Oncology (HKSE:09966), the current Enterprise Value is HK$6,451.9 Mil as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alphamab Oncology (HKSE:09966) Overvalued in 2026?
Based on GuruFocus' analysis, Alphamab Oncology stock appears to be overvalued.
The current stock price of HK$8.35 is trading 6.9% above its estimated GF Value™ of HK$7.81.
GuruFocus considers Alphamab Oncology to be Fairly Valued.
Key valuation signals for HKSE:09966:
Enterprise Value: HK$6,451.9 Mil
GF Value™: HK$7.81 vs. price of HK$8.35 (6.9% above fair value)
No single metric tells the full story. See the HKSE:09966 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
55GF Score
Get the complete analysis for HKSE:09966
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09966 has been successfully added to your 
